NEW YORK (GenomeWeb) – Sophia Genetics said today that it has closed on a $77 million Series E round of venture capital, led by new investor Generation Investment Management, with participation from Idinvest Partners and previous Sophia equity backers Balderton Capital and Alychlo.

Sophia, which now has co-headquarters in Boston and Lausanne, Switzerland, said that it will apply much of the new funding to expand its US presence by growing its workforce and marketing to more American hospitals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.